NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $136.02 -0.93 (-0.68%) As of 03:19 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neurocrine Biosciences Stock (NASDAQ:NBIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$135.80▼$138.2050-Day Range$135.13▼$164.9252-Week Range$122.14▼$186.12Volume435,609 shsAverage Volume1.22 million shsMarket Capitalization$13.83 billionP/E Ratio19.94Dividend YieldN/APrice Target$201.14Consensus RatingModerate Buy Company Overview Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies. Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease. The company also markets ONGENTYS (opicapone), an adjunctive treatment for “off” episodes in adults with Parkinson’s disease receiving levodopa and carbidopa. Its portfolio has also included therapies developed through partnerships, such as elagolix, which was commercialized by AbbVie for certain women’s health conditions. Founded in 1992, Neurocrine has built its business around treatments for conditions with significant unmet medical needs. In 2024, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement therapy for adults and children with classic congenital adrenal hyperplasia. The company primarily serves the U.S. market while pursuing international commercialization through regional partners and license agreements. Neurocrine is led by Chief Executive Officer Kyle Gano, who has held leadership positions with the company since joining in 2011.AI Generated. May Contain Errors. Read More Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreNBIX MarketRank™: 4.83635415308 of 5 starsNeurocrine Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 5th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 19 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialNeurocrine Biosciences has a consensus price target of $201.14, representing about 48.1% upside from its current price of $135.86.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth22.86% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 22.86% in the coming year, from $7.70 to $9.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 19.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 19.94, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.18.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.60. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.04% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 17.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentNeurocrine Biosciences has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Neurocrine Biosciences this week, compared to 7 articles on an average week.Search Interest8 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $720,855.00 in company stock.Percentage Held by Insiders4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Stock News HeadlinesNeurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaOctober 16 at 8:30 AM | prnewswire.comWhy Neurocrine Biosciences (NBIX) is a top value stock for the long termOctober 14 at 8:02 PM | msn.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.October 16 at 1:00 AM | American Alternative (Ad)BMO Capital Markets Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock PriceOctober 14 at 1:19 AM | americanbankingnews.comNeurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC SaysOctober 13 at 6:14 PM | finance.yahoo.comAxsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?October 13 at 6:14 PM | finance.yahoo.comWhy Neurocrine Biosciences (NBIX) is a top growth stock for the long termOctober 13 at 1:13 PM | msn.comDavid Boyer Sells 826 Shares of Neurocrine Biosciences (NASDAQ:NBIX) StockSeptember 16, 2026 | insidertrades.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $141.83 at the start of the year. Since then, NBIX shares have decreased by 4.2% and is now trading at $135.8550. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Friday, July, 31st. The company reported $2.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.65 by $1.20. Neurocrine Biosciences's revenue for the quarter was up 39.5% compared to the same quarter last year. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' board authorized a stock repurchase plan on Friday, February 21st 2025, which authorizes the company to repurchase $500,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 4.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's leadership believes its shares are undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional shareholders include Ninety One UK Ltd (0.43%), Assenagon Asset Management S.A. (0.14%), Congress Asset Management Co. (0.12%) and Argent Capital Management LLC (0.02%). Insiders that own company stock include Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Darin Lippoldt, Matt Abernethy, Eric Benevich, William H Rastetter, Richard F Pops, Jude Onyia, Eiry Roberts, Julie Cooke, Ingrid Delaet, Stephen A Sherwin, David W Boyer and Shalini Sharp. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Walt Disney (DIS), AbbVie (ABBV), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings7/31/2026Today10/16/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, NBIX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees2,000Year Founded1992Price Target and Rating Average Price Target for Neurocrine Biosciences$201.14 High Price Target$253.00 Low Price Target$150.00 Potential Upside/Downside+48.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$6.82 Trailing P/E Ratio19.94 Forward P/E Ratio17.64 P/E Growth0.6Net Income$478.60 million Net Margins20.91% Pretax Margin27.87% Return on Equity22.43% Return on Assets15.64% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.75 Sales & Book Value Annual Sales$3.37 billion Price / Sales4.09 Cash Flow$5.01 per share Price / Cash Flow27.11 Book Value$32.63 per share Price / Book4.16Miscellaneous Outstanding Shares101,649,000Free Float96,973,000Market Cap$13.81 billion OptionableOptionable Beta0.40 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:NBIX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
